A recent systematic review and meta-analysis confirmed a MGMT methylation status as a clinical biomarker in GBM patients, showing association with better overall and progression-free survival in patients treated with alkylating agents [88] and tyrosine kinase inhibitors [89]. This evidence concerns the gene MGMT and glioblastoma.